0000899243-17-002743.txt : 20170203 0000899243-17-002743.hdr.sgml : 20170203 20170203171302 ACCESSION NUMBER: 0000899243-17-002743 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170201 FILED AS OF DATE: 20170203 DATE AS OF CHANGE: 20170203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1030 MASSACHUSETTS AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 1030 MASSACHUSETTS AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TEPPER ROBERT I CENTRAL INDEX KEY: 0001192595 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 17573019 MAIL ADDRESS: STREET 1: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-01 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001192595 TEPPER ROBERT I C/O THIRD ROCK VENTURES, LLC 29 NEWBURY STREET, 3RD FLOOR BOSTON MA 02116 1 0 1 0 Common Stock 2017-02-01 4 C 0 9688344 A 10230349 I See Footnote Common Stock 2017-02-01 4 C 0 3048780 A 3048780 I See Footnote Series A Preferred Stock 2017-02-01 4 C 0 35750000 0.00 D Common Stock 9688344 0 I See Footnote Series A Preferred Stock 2017-02-01 4 C 0 11250000 0.00 D Common Stock 3048780 0 I See Footnote Represents the total number of shares of Common Stock received by Third Rock Ventures II, L.P. ("TRV II") upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Represents the total number of shares of Common Stock received by Third Rock Ventures III, L.P. ("TRV III") upon conversion of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Each share of Series A Preferred Stock converted into Common Stock on a one-for-3.69 basis upon the closing of the Issuer's initial public offering without payment or consideration. Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any. These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. /s/ Kevin Gillis by power of attorney for Dr. Robert Tepper 2017-02-03